Gamco Investors INC. ET AL Invests $200,000 in Harvard Bioscience, Inc. (NASDAQ:HBIO)

Gamco Investors INC. ET AL bought a new stake in Harvard Bioscience, Inc. (NASDAQ:HBIO) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 95,000 shares of the medical instruments supplier’s stock, valued at approximately $200,000. Gamco Investors INC. ET AL owned approximately 0.22% of Harvard Bioscience at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. AMH Equity Ltd raised its position in Harvard Bioscience by 4.7% during the fourth quarter. AMH Equity Ltd now owns 2,500,000 shares of the medical instruments supplier’s stock valued at $5,275,000 after acquiring an additional 111,132 shares in the last quarter. Royce & Associates LP boosted its stake in shares of Harvard Bioscience by 35.4% during the 4th quarter. Royce & Associates LP now owns 1,965,114 shares of the medical instruments supplier’s stock worth $4,146,000 after acquiring an additional 513,664 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Harvard Bioscience by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 912,599 shares of the medical instruments supplier’s stock worth $2,455,000 after purchasing an additional 19,972 shares during the last quarter. State Street Corp grew its holdings in Harvard Bioscience by 1.1% during the third quarter. State Street Corp now owns 717,387 shares of the medical instruments supplier’s stock valued at $1,930,000 after purchasing an additional 7,763 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Harvard Bioscience by 11.1% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 200,032 shares of the medical instruments supplier’s stock valued at $422,000 after purchasing an additional 20,026 shares during the period. 80.87% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. KeyCorp reiterated a “sector weight” rating on shares of Harvard Bioscience in a research note on Wednesday, April 9th. StockNews.com initiated coverage on Harvard Bioscience in a research note on Sunday. They set a “hold” rating for the company. Finally, Benchmark dropped their price target on Harvard Bioscience from $5.50 to $4.50 and set a “speculative buy” rating on the stock in a research report on Monday, March 24th.

Harvard Bioscience Stock Down 0.5 %

Shares of HBIO opened at $0.39 on Friday. Harvard Bioscience, Inc. has a 52 week low of $0.36 and a 52 week high of $4.08. The firm has a market capitalization of $17.10 million, a P/E ratio of -1.18 and a beta of 1.47. The company has a 50-day simple moving average of $0.71 and a 200-day simple moving average of $1.65. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.91 and a current ratio of 2.06.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.